Allison Bratzel

Li Watsek

Roger Song

Sam Slutsky

Ting Liu

Yu He (Arthur)

- ALX Oncology Holdings Inc. appointed **Barbara Klencke, M.D.**, as Interim Chief Medical Officer, effective **September 17, 2025**.  **[1810182_0001810182-25-000006_alxo-ex99_1.htm:0]** **[1810182_0001810182-25-000006_alxo-20250911.htm:2]**  Dr. Klencke will resign from the Board of Directors to assume this role.  **[1810182_0001810182-25-000006_alxo-ex99_1.htm:0]** **[1810182_0001810182-25-000006_alxo-20250911.htm:1]** 
- **Alan Sandler, M.D.**, resigned as Chief Medical Officer, effective **September 26, 2025**, and will return to his role on the Company's Board of Directors, effective the same date.  **[1810182_0001810182-25-000006_alxo-ex99_1.htm:0]** **[1810182_0001810182-25-000006_alxo-20250911.htm:1]** **[1810182_0001810182-25-000006_alxo-20250911.htm:2]** 
- The company regained compliance with the Nasdaq minimum bid price requirement on **September 4, 2025**, having maintained a closing bid price of at least **$1.00** for ten consecutive business days.  **[1810182_0001810182-25-000006_alxo-20250911.htm:2]**

ALX ONCOLOGY HOLDINGS (ALXO)